{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T23:05:24Z","timestamp":1779836724470,"version":"3.53.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["EJNMMI Phys"],"DOI":"10.1186\/s40658-026-00852-w","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T12:58:15Z","timestamp":1776344295000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Gravity versus pump-driven infusion in targeted radionuclide therapy: a model-based dosimetric evaluation of extravasation"],"prefix":"10.1186","volume":"13","author":[{"given":"Olivia","family":"Lienhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oreste","family":"Allegrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Poterszman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Ritzenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"Porot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Mazzara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Somme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3823-2531","authenticated-orcid":false,"given":"Julien","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"issue":"2","key":"852_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of$$^{\\rm 177 }$$ lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1607427.","journal-title":"N Engl J Med"},{"issue":"12","key":"852_CR2","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, De Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa2107322.","journal-title":"N Engl J Med"},{"issue":"8","key":"852_CR3","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.2967\/jnumed.124.269411","volume":"66","author":"G Kayal","year":"2025","unstructured":"Kayal G, Augensen F, Bodei L, Chu B, Marquis H, Carter LM, et al. Extravasation frequency of [177lu]lu-DOTATATE: Insights and implications derived from 1,314 cycles of treated patients-a single-site analysis. J Nucl Med. 2025;66(8):1258\u201364. https:\/\/doi.org\/10.2967\/jnumed.124.269411.","journal-title":"J Nucl Med"},{"issue":"7","key":"852_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1007\/s00259-017-3675-7","volume":"44","author":"J van der Pol","year":"2017","unstructured":"van der Pol J, V\u00f6\u00f6 S, Bucerius J, Mottaghy FM. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review. Eur J Nucl Med Mol Imaging. 2017;44(7):1234\u201343. https:\/\/doi.org\/10.1007\/s00259-017-3675-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"852_CR5","doi-asserted-by":"publisher","first-page":"1219202","DOI":"10.3389\/fnume.2023.1219202","volume":"3","author":"DR Osborne","year":"2023","unstructured":"Osborne DR. Radiopharmaceutical extravasations: a twenty year mini-review. Front Nuclear Med. 2023;3:1219202. https:\/\/doi.org\/10.3389\/fnume.2023.1219202.","journal-title":"Front Nuclear Med"},{"issue":"13","key":"852_CR6","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.3390\/cancers16132308","volume":"16","author":"TD Pham","year":"2024","unstructured":"Pham TD, Tsunoyama T. Exploring extravasation in cancer patients. Cancers. 2024;16(13):2308. https:\/\/doi.org\/10.3390\/cancers16132308.","journal-title":"Cancers"},{"issue":"8","key":"852_CR7","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1097\/RLU.0000000000001715","volume":"42","author":"CD Schlenkhoff","year":"2017","unstructured":"Schlenkhoff CD, Essler M, Ahmadzadehfar H. Possible treatment approach to an extravasation of 177lu-PSMA-617. Clin Nucl Med. 2017;42(8):639\u201340. https:\/\/doi.org\/10.1097\/RLU.0000000000001715.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"852_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1055\/s-0038-1641692","volume":"57","author":"M J\u00fcptner","year":"2018","unstructured":"J\u00fcptner M, Zuhayra M, Assam I, L\u00fctzen U. Successful handling of an accidental extravasation of 177lu-PSMA-617 in the treatment of advanced prostate cancer. Nuklearmedizin. 2018;57(2):10\u20132. https:\/\/doi.org\/10.1055\/s-0038-1641692.","journal-title":"Nuklearmedizin"},{"issue":"1","key":"852_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13550-020-00658-6","volume":"10","author":"AK Arveschoug","year":"2020","unstructured":"Arveschoug AK, Bekker AC, Iversen P, Bluhme H, Villadsen GE, Staanum PF. Extravasation of [177lu]lu-DOTATOC: case report and discussion. EJNMMI Res. 2020;10(1):68. https:\/\/doi.org\/10.1186\/s13550-020-00658-6.","journal-title":"EJNMMI Res"},{"issue":"1","key":"852_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-021-00378-3","volume":"8","author":"P Tylski","year":"2021","unstructured":"Tylski P, Pina-Jomir G, Bournaud-Salinas C, Jalade P. Tissue dose estimation after extravasation of 177lu-DOTATATE. EJNMMI Phys. 2021;8(1):33. https:\/\/doi.org\/10.1186\/s40658-021-00378-3.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"852_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/RLU.0000000000003452","volume":"46","author":"B Maucherat","year":"2021","unstructured":"Maucherat B, Varmenot N, Fleury V, Senellart H, Rousseau C. Effective management of 177lu-DOTA0-lr3-octreotate extravasation. Clin Nucl Med. 2021;46(2):144\u20135. https:\/\/doi.org\/10.1097\/RLU.0000000000003452.","journal-title":"Clin Nucl Med"},{"issue":"2","key":"852_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/HP.0000000000001558","volume":"123","author":"K Berry","year":"2022","unstructured":"Berry K, Kendrick J. Lutetium-177 radiopharmeceutical therapy extravasation lessons learned. Health Phys. 2022;123(2):160\u20134. https:\/\/doi.org\/10.1097\/HP.0000000000001558.","journal-title":"Health Phys"},{"key":"852_CR13","doi-asserted-by":"publisher","unstructured":"De Vries-Huizing DMV, Cheung ZJ, Hendrikx JJMA, Donswijk ML, Versleijen MWJ. Extravasation after [177lu]lu-HA-DOTATATE therapy. Clinical Nuclear Med 2024;49(5) . https:\/\/doi.org\/10.1097\/RLU.0000000000005137.","DOI":"10.1097\/RLU.0000000000005137"},{"issue":"2","key":"852_CR14","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.mednuc.2025.01.168","volume":"49","author":"A B\u00e9ron","year":"2025","unstructured":"B\u00e9ron A, Delhay A, Prang\u00e8re T, Maurice JB, Pontvianne V, Pasquesoone L, et al. Prise en charge d\u2019une extravasation significative lors d\u2019un traitement par 177lu-PSMA. M\u00e9decine Nucl\u00e9aire. 2025;49(2):102. https:\/\/doi.org\/10.1016\/j.mednuc.2025.01.168.","journal-title":"M\u00e9decine Nucl\u00e9aire"},{"issue":"4","key":"852_CR15","doi-asserted-by":"publisher","first-page":"288","DOI":"10.2967\/jnmt.118.221846","volume":"47","author":"AB Davis","year":"2019","unstructured":"Davis AB, Pietryka MH, Passalaqua S. Technical aspects and administration methods of$$^{\\rm 177 }$$ lu-DOTATATE for nuclear medicine technologists. J Nucl Med Technol. 2019;47(4):288\u201391. https:\/\/doi.org\/10.2967\/jnmt.118.221846.","journal-title":"J Nucl Med Technol"},{"key":"852_CR16","unstructured":"Ellis A, Lawson S, Rybicki L, ACKERMANN R, Newton R, Frey K, Wong KK. Comparison of four infusion methods for lutathera peptide radionuclide receptor therapy. J. Nuclear Med 2021;62, 182 ."},{"issue":"7","key":"852_CR17","doi-asserted-by":"publisher","first-page":"937","DOI":"10.2967\/jnumed.118.230607","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Abbott A, Colucci K, Bushnell DL, Gardner L, Graham WS, et al. NANETS\/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with$$^{{\\rm 177}}$$ lu-DOTATATE. J Nucl Med. 2019;60(7):937\u201343. https:\/\/doi.org\/10.2967\/jnumed.118.230607.","journal-title":"J Nucl Med"},{"issue":"1","key":"852_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40658-022-00466-y","volume":"9","author":"C Mazzara","year":"2022","unstructured":"Mazzara C, Salvadori J, Ritzenthaler F, Martin S, Porot C, Imperiale A. 177lu-DOTA-0-tyr3-octreotate infusion modeling for real-time detection and characterization of extravasation during PRRT. EJNMMI Phys. 2022;9(1):33. https:\/\/doi.org\/10.1186\/s40658-022-00466-y.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"852_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1088\/0031-9155\/13\/2\/306","volume":"13","author":"R Loevinger","year":"1968","unstructured":"Loevinger R, Berman M. A formalism for calculation of absorbed dose from radionuclides. Phys Med Biol. 1968;13(2):205\u201317. https:\/\/doi.org\/10.1088\/0031-9155\/13\/2\/306.","journal-title":"Phys Med Biol"},{"issue":"3","key":"852_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD Pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry-standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","journal-title":"J Nucl Med"},{"key":"852_CR21","doi-asserted-by":"publisher","unstructured":"Sarrut D, Arbor N, Baudier T, Bert J, Chatzipapas K, Favaretto M, Fuchs H, Grevillot L, Harb H, Van Hoey G, Jacquet M, Jan S, Jia Y, Kagadis GC, Kang HG, Klever P, Kochebina O, Krzemien W, Maigne L, Mohr P, Mummaneni G, Paneta V, Papadimitroulas P, Pereda A, Rannou A, Resch AF, Roncali E, Toussaint M, Trigila C, Tsoumpas C, Zhang J, Ziemons K, Krah N. GATE 10 Monte Carlo particle transport simulation - Part I: development and new features. arXiv. Version Number: 2025;2 . https:\/\/doi.org\/10.48550\/ARXIV.2507.09842.","DOI":"10.48550\/ARXIV.2507.09842"},{"key":"852_CR22","doi-asserted-by":"publisher","unstructured":"Krah N, Arbor N, Baudier T, Bert J, Chatzipapas K, Favaretto M, Fuchs H, Grevillot L, Harb H, Van Hoey G, Jacquet M, Jan S, Jia Y, Kagadis GC, Kang HG, Klever P, Kochebina O, Maigne L, Mohr P, Mummaneni G, Paneta V, Papadimitroulas P, Pereda A, Rannou A, Resch AF, Roncali E, Toussaint M, Trigila C, Tsoumpas C, Zhang J, Ziemons K, Sarrut D. GATE 10 Monte Carlo particle transport simulation - Part II: architecture and innovations. arXiv. Version Number: 2025;2 . https:\/\/doi.org\/10.48550\/ARXIV.2507.09840.","DOI":"10.48550\/ARXIV.2507.09840"},{"key":"852_CR23","doi-asserted-by":"crossref","unstructured":"Merck Manuals Professional Editorial Board: Radiation Injury (2025). https:\/\/www.merckmanuals.com\/professional\/injuries-and-poisoning\/radiation-exposure-and-contamination\/radiation-exposure-and-contamination Accessed 2025\u201303-10.","DOI":"10.1016\/S2452-1094(25)00201-5"},{"key":"852_CR24","unstructured":"International Atomic Energy Agency (IAEA): Radiation Protection of Patients (RPoP): Radiation Effects on Skin (2017). https:\/\/www.iaea.org\/resources\/rpop\/health-professionals\/radiology\/radiation-effects-on-skin Accessed 2025\u201303-10."},{"issue":"1","key":"852_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.2214\/ajr.177.1.1770003","volume":"177","author":"TR Koenig","year":"2001","unstructured":"Koenig TR, Wolff D, Mettler FA, Wagner LK. Skin injuries from fluoroscopically guided procedures: Part 1, characteristics of radiation injury. Am J Roentgenol. 2001;177(1):3\u201311. https:\/\/doi.org\/10.2214\/ajr.177.1.1770003.","journal-title":"Am J Roentgenol"},{"key":"852_CR26","unstructured":"National Council on Radiation Protection and Measurements (NCRP): Radiation dose management for fluoroscopically-guided interventional medical procedures. Technical Report NCRP Report No. 168, National Council on Radiation Protection and Measurements, Bethesda, MD (2010). DOI: 10.1097\/HP.0b013e3181fcbdbf."},{"issue":"5","key":"852_CR27","first-page":"892","volume":"32","author":"SL Breen","year":"1991","unstructured":"Breen SL, Driedger AA. Radiation injury from interstitial injection of iodine-131-iodocholesterol. J Nuclear Med. 1991;32(5):892.","journal-title":"J Nuclear Med"},{"issue":"9","key":"852_CR28","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.2967\/jnumed.110.083725","volume":"52","author":"DV Bonta","year":"2011","unstructured":"Bonta DV, Halkar RK, Alazraki N. Extravasation of a therapeutic dose of 131i-metaiodobenzylguanidine: Prevention, dosimetry, and mitigation. J Nucl Med. 2011;52(9):1418\u201322. https:\/\/doi.org\/10.2967\/jnumed.110.083725.","journal-title":"J Nucl Med"},{"issue":"2","key":"852_CR29","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1188\/08.CJON.275-278","volume":"12","author":"BM Siebeneck","year":"2008","unstructured":"Siebeneck BM. Extravasation of yttrium-90 ibritumomab tiuxetan: A case study. Clin J Oncol Nurs. 2008;12(2):275\u20138. https:\/\/doi.org\/10.1188\/08.CJON.275-278.","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"852_CR30","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.anplas.2017.11.007","volume":"63","author":"A Baus","year":"2018","unstructured":"Baus A, Keilani C, Bich C-S, Entine F, Brachet M, Duhamel P, et al. Complex upper arm reconstruction using an antero-lateral thigh free flap after an extravasation of yttrium-90-ibritumomab tiuxetan: A case report and literature review. Annales de Chirurgie Plastique Esth\u00e9tique. 2018;63(2):175\u201381. https:\/\/doi.org\/10.1016\/j.anplas.2017.11.007.","journal-title":"Annales de Chirurgie Plastique Esth\u00e9tique"}],"container-title":["EJNMMI Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40658-026-00852-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-026-00852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40658-026-00852-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T22:35:39Z","timestamp":1779834939000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40658-026-00852-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["852"],"URL":"https:\/\/doi.org\/10.1186\/s40658-026-00852-w","relation":{},"ISSN":["2197-7364"],"issn-type":[{"value":"2197-7364","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"assertion":[{"value":"11 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed written consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"55"}}